Browse the corpus

Pulmonary arterial hypertension (PAH) contributes substantially to global morbidity and mortality due to progressive vascular remodeling and increased pulmonary vascular resistance. Endothelin 1 overexpression plays a central role in vasoconstriction, smooth muscle proliferation, and endothelial dysfunction in affected patients. Bosentan, a dual endothelin receptor antagonist, mitigates these pathogenic processes by competitively inhibiting endothelin A and B receptors, thereby reducing pulmonary arterial pressure and improving cardiac output. Clinical indications include idiopathic and heritable PAH, as well as PAH arising from connective tissue disease or congenital heart defects. Randomized controlled trials have demonstrated bosentan’s efficacy in improving exercise capacity, functional class, and hemodynamic parameters. Administration requires oral dosing with careful titration and periodic liver function monitoring due to potential hepatotoxicity. Common adverse effects include peripheral edema, headache, and anemia. Bosentan’s integration into PAH management has significantly altered disease progression and patient outcomes, establishing endothelin receptor antagonism as a cornerstone of 1st-line therapy. This activity for healthcare professionals is designed to improve learners' proficiency in the safe and effective use of bosentan. Participants will deepen their understanding of this drug's mechanism of action, evidence base, indications, off-label applications, administration, efficacy, safety profile, monitoring parameters, comparative effectiveness, and clinical considerations. Enhanced competence will equip clinicians to collaborate successfully with interprofessional teams in optimizing PAH therapy and tailoring treatment to individual patient needs. Objectives: Assess patients for suitability for bosentan therapy based on clinical presentation, risk factors, and laboratory or imaging findings. Apply evidence-based, personalized strategies for delivering safe and effective bosentan therapy while addressing comorbidities and potential drug interactions. Determine optimal monitoring protocols for patients receiving bosentan therapy to ensure safe dosing, therapeutic efficacy, and minimization of drug-related complications.

Apply evidence-based, personalized strategies for delivering safe and effective bosentan therapy while addressing comorbidities and potential drug interactions. Determine optimal monitoring protocols for patients receiving bosentan therapy to ensure safe dosing, therapeutic efficacy, and minimization of drug-related complications. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who may benefit from bosentan therapy. Access free multiple choice questions on this topic.

The most frequently observed adverse effect of bosentan overdose is headache. In a cyclosporine A interaction study, administration of 500 mg and 1,000 mg of bosentan twice daily in combination with cyclosporine A resulted in a 30-fold increase in trough plasma concentrations, leading to severe headache, nausea, and vomiting. No serious adverse events were reported. Additional findings included hypotension and tachycardia. During one postmarketing period, a male patient ingested 10,000 mg of bosentan, which resulted in nausea, vomiting, hypotension, blurred vision, and diaphoresis. The patient achieved full recovery following appropriate blood pressure support.

Prior to the introduction of bosentan, treatment options for PAH were limited to intravenous therapies, such as epoprostenol. Bosentan has since become a 1st-line therapy for PAH, demonstrating efficacy as monotherapy or, more frequently, part of combination regimens. The drug's favorable safety profile, oral administration, clinical effectiveness, and disease-modifying potential make it a cornerstone of PAH management. Ongoing research is necessary to identify combination strategies that optimize outcomes while minimizing toxicity. Prescribers must initiate bosentan judiciously, performing baseline and ongoing LFT assessments and adhering to boxed warnings. Pulmonologists are responsible for optimizing therapy and evaluating clinical response. Advanced practice providers can initiate treatment, monitor adherence, educate patients on hepatotoxicity and embryofetal risks, and ensure timely laboratory follow-up. Nurses monitor for signs of liver injury and reinforce appropriate contraceptive use. Pharmacists review prescriptions for safety, assess potential drug-drug interactions, and ensure compliance with REMS and boxed warning requirements. Interprofessional collaboration is essential to mitigate hepatic and fetal complications and ensure the safe and effective use of bosentan. A multicenter randomized trial involving 92 patients with pulmonary hypertension across 10 French university hospitals demonstrated that inclusion of clinical pharmacists in the care team significantly improved the resolution of drug-related problems compared to usual care (86.5% versus 66.7%). Pharmacists conducted individualized interviews, reviewed medication regimens, educated patients, and communicated recommendations to physicians and nurses through collaborative discussions. This model also reduced the costs associated with drug-related hospitalizations, highlighting the value of interprofessional collaboration.[50] An interprofessional team approach is recommended in the management of PAH with bosentan. Primary care physicians, advanced practice providers, pulmonologists, cardiologists, specialty-trained nurses, and pharmacists should collaborate to optimize treatment outcomes, minimize adverse effects, and reduce the risk of drug-drug interactions.